Global Anticoagulation Therapy Market – Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Published Report
  • Dec 2018
  • Global
  • 350 Pages
  • No of Tables: 517
  • No of Figures: 50

Global Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Geography (Europe, North America, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2026

Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open. Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi. There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).

 Global anticoagulation therapy market is projected to register a substantial CAGR of 8.3% in the forecast period of 2019 to 2026.

Segmentation: Global Anticoagulation Therapy Market

Global anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.

  • On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and others
  • On the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and others

    • In July 2015, Sandoz AG, a division of Novartis AG, launched bivalirudin a generic version of ANGIOMAX in 250 mg of single-dose vial. This product launch will help to grow Novartis AG product portfolio and the company revenue.

  • On the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and others.
  • On the basis of route of administration, the market is segmented into oral and injectable
  • On the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and others
  • On the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacement
  • On the basis of type, the market is segmented into generics and branded
  • On the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and others
  • On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy

Competitive Analysis: Global Anticoagulation Therapy Market

Some of the major players operating in the global anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical(Group)Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.

Product Launch

  • In November 2018, Daiichi Sankyo Company, Limited launched LIXIANA in Japan. It is a branded version of edoxaban. It is administered to reduce the chance of systemic embolism (SE) and stroke in patients who are having non-valvular atrial fibrillation (NVAF). This product launch will help the company to expand its business in Japan.
  • In August 2018, Fresenius Kabi launched four new heparin sodium in freeflex containers that is an advanced IVcontainer technology. The major benefits of this product launch will help to expand the portfolio of ready-toadminister and convenient medicines in non-DEHP bags and as well as in prefilled syringes.
  • In June, 2018, Mylan N.V. has launched Angiomax’s generic vesion Bivalirudin in 250 mg single-dose vial in injectable form. This product launch will help company to increase its market share in global anticoagulation therapy.

Research Methodology: Global Anticoagulation Therapy Market

Primary Rependants:

Key Opinion Leaders (KOL’s): Manufacturers, Researchers, Distributors, Bakers and Food Industrialists.

Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and National Sales Managers.


SKU-

TABLE 1 AGEING WORLD POPULATION

TABLE 2 POSTOPERATIVE PULMONARY EMBOLISM OR DEEP VEIN THROMBOSIS IN HIP AND KNEE SURGERIES, 2015

TABLE 3 GLOBAL ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 4 GLOBAL DEEP VEIN THROMBOSIS (DVT) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 5 GLOBAL PULMONARY EMBOLISM (PE) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 6 GLOBAL ARTERIAL THROMBOEMBOLISM (AT) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 7 GLOBAL STROKE IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 8 GLOBAL OTHERS IN GLOBAL ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 9 GLOBAL ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 10 GLOBAL NOVEL ORAL ANTICOAGUALTANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 11 GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 12 GLOBAL HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 13 GLOBAL HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 14 GLOBAL VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 15 GLOBAL VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 16 GLOBAL OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 17 GLOBAL ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 18 GLOBAL BIVALIRUDIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 19 GLOBAL DABIGATRAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 20 GLOBAL EDOXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 21 GLOBAL BETRIXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 22 GLOBAL RIVAROXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 23 GLOBAL APIXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 24 GLOBAL ENOXAPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 25 GLOBAL DALTEPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 26 GLOBAL OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 27 GLOBAL ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION , 2017-2026 (USD MILLION)

TABLE 28 GLOBAL ORAL IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 29 GLOBAL INJECTABLES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 30 GLOBAL INJECTABLES IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 31 GLOBAL ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 32 GLOBAL CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 33 GLOBAL CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 34 GLOBAL ONCOLOGY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 35 GLOBAL RESPIRATORY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 36 GLOBAL NEPHROLOGY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 37 GLOBAL CNS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 38 GLOBAL OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 39 GLOBAL ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 40 GLOBAL PRE-SURGICAL PROCEDURES IN GLOBAL ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 41 GLOBAL POST-SURGICAL PROCEDURES IN GLOBAL ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 42 GLOBAL KIDNEY DIALYSIS IN GLOBAL ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 43 GLOBAL HEART VALVE REPLACEMENT IN GLOBAL ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 44 GLOBAL ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 45 GLOBAL GENERICS IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 46 GLOBAL BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 47 GLOBAL BRANDED IN GLOBAL ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 48 GLOBAL ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 49 GLOBAL HOSPITALS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 50 GLOBAL CLINICS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 51 GLOBAL HOMECARE IN ANTICOAGULATION THERAPY MARKET,BY REGION, 2017-2026 (USD MILLION)

TABLE 52 GLOBAL AMBULATORY SURGICAL CENTERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 53 GLOBAL OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 54 GLOBAL ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 55 GLOBAL HOSPITAL PHARMACY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 56 RETAIL PHARMACIES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 57 GLOBAL ONLINE PHARMACIES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 58 GLOBAL ANTICOAGULATION THERAPY MARKET, BY GEOGRAPHY, 2017-2026 (USD MILLION)

TABLE 59 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY COUNTRY, 2017-2026 (USD MILLION)

TABLE 60 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 61 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 62 NORTH AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 63 NORTH AMERICA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 64 NORTH AMERICA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 65 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 66 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 67 NORTH AMERICA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 68 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 69 NORTH AMERICA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 70 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 71 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 72 NORTH AMERICA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 73 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 74 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 75 U.S. ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 76 U.S. ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 77 U.S. NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 78 U.S. HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 79 U.S. VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 80 U.S. ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 81 U.S. ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 82 U.S. INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 83 U.S.ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 84 U.S. CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 85 U.S. ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 86 U.S. ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 87 U.S. BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 88 U.S. ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 89 U.S. ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 90 CANADA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 91 CANADA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 92 CANADA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 93 CANADA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 94 CANADA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 95 CANADA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 96 CANADA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 97 CANADA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 98 CANADA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 99 CANADA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 100 CANADA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 101 CANADA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 102 CANADA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 103 CANADA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 104 CANADA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 105 MEXICO ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 106 MEXICO ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 107 MEXICO NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 108 MEXICO HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 109 MEXICO VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 110 MEXICO ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 111 MEXICO ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 112 MEXICO INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 113 MEXICO ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 114 MEXICO CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 115 MEXICO ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 116 MEXICO ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 117 MEXICO BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 118 MEXICO ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 119 MEXICO ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 120 EUROPE ANTICOAGULATION THERAPY MARKET, BY COUNTRY, 2017-2026 (USD MILLION)

TABLE 121 EUROPE ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 122 EUROPE ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 123 EUROPE NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 124 EUROPE HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 125 EUROPE VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 126 EUROPE ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 127 EUROPE ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 128 EUROPE INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 129 EUROPE ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 130 EUROPE CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 131 EUROPE ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 132 EUROPE ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 133 EUROPE BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION))

TABLE 134 EUROPE ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 135 EUROPE ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 136 GERMANY ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 137 GERMANY ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 138 GERMANY NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 139 GERMANY HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 140 GERMANY VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 141 GERMANY ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 142 GERMANY ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 143 GERMANY INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 144 GERMANY ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 145 GERMANY CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 146 GERMANY ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 147 GERMANY ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 148 GERMANY BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 149 GERMANY ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 150 GERMANY ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 151 FRANCE ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 152 FRANCE ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 153 FRANCE NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 154 FRANCE HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 155 FRANCE VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 156 FRANCE ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 157 FRANCE ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 158 FRANCE INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 159 FRANCE ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 160 FRANCE CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 161 FRANCE ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 162 FRANCE ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 163 FRANCE BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 164 FRANCE ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 165 FRANCE ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 166 ITALY ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 167 ITALY ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 168 ITALY NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 169 ITALY HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 170 ITALY VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 171 ITALY ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 172 ITALY ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 173 ITALY INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 174 ITALY ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 175 ITALY CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 176 ITALY ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 177 ITALY ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 178 ITALY BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 179 ITALY ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 180 ITALY ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 181 U.K. ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 182 U.K. ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 183 U.K. NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 184 U.K. HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 185 U.K. VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 186 U.K. ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 187 U.K. ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 188 U.K. INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 189 U.K. ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 190 U.K. CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 191 U.K. ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 192 U.K. ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 193 U.K. BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 194 U.K. ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 195 U.K. ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 196 SPAIN ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 197 SPAIN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 198 SPAIN NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 199 SPAIN HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 200 SPAIN VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 201 SPAIN ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 202 SPAIN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 203 SPAIN INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 204 SPAIN ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 205 SPAIN CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 206 SPAIN ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 207 SPAIN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 208 SPAIN BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 209 SPAIN ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 210 SPAIN ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 211 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 212 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 213 SWITZERLAND NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 214 SWITZERLAND HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 215 SWITZERLAND VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 216 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 217 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 218 SWITZERLAND INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 219 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 220 SWITZERLAND CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 221 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 222 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 223 SWITZERLAND BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 224 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 225 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 226 RUSSIA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 227 RUSSIA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 228 RUSSIA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 229 RUSSIA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 230 RUSSIA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 231 RUSSIA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 232 RUSSIA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 233 RUSSIA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 234 RUSSIA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 235 RUSSIA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 236 RUSSIA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 237 RUSSIA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 238 RUSSIA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 239 RUSSIA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 240 RUSSIA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 241 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 242 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 243 NETHERLANDS NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 244 NETHERLANDS HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 245 NETHERLANDS VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 246 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 247 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 248 NETHERLANDS INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 249 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 250 NETHERLANDS CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 251 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 252 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 253 NETHERLANDS BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 254 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 255 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 256 BELGIUM ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 257 BELGIUM ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 258 BELGIUM NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 259 BELGIUM HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 260 BELGIUM VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 261 BELGIUM ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 262 BELGIUM ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 263 BELGIUM INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 264 BELGIUM ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 265 BELGIUM CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 266 BELGIUM ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 267 BELGIUM ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 268 BELGIUM BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 269 BELGIUM ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 270 BELGIUM ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 271 TURKEY ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 272 TURKEY ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 273 TURKEY NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 274 TURKEY HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 275 TURKEY VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 276 TURKEY ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 277 TURKEY ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 278 TURKEY INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 279 TURKEY ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 280 TURKEY CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 281 TURKEY ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 282 TURKEY ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 283 TURKEY BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 284 TURKEY ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 285 TURKEY ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 286 REST OF EUROPE ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 287 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY COUNTRY, 2017-2026 (USD MILLION)

TABLE 288 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 289 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 290 ASIA-PACIFIC NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 291 ASIA-PACIFIC HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 292 ASIA-PACIFIC VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 293 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 294 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 295 ASIA-PACIFIC INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 296 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 297 ASIA-PACIFIC CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 298 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 299 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 300 ASIA-PACIFIC BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION))

TABLE 301 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 302 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 303 JAPAN ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 304 JAPAN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 305 JAPAN NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 306 JAPAN HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 307 JAPAN VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 308 JAPAN ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 309 JAPAN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 310 JAPAN INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 311 JAPAN ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 312 JAPAN CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 313 JAPAN ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 314 JAPAN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 315 JAPAN BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 316 JAPAN ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 317 JAPAN ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 318 CHINA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 319 CHINA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 320 CHINA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 321 CHINA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 322 CHINA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 323 CHINA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 324 CHINA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 325 CHINA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 326 CHINA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 327 CHINA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 328 CHINA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 329 CHINA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 330 CHINA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 331 CHINA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 332 CHINA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 333 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 334 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 335 SOUTH KOREA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 336 SOUTH KOREA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 337 SOUTH KOREA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 338 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 339 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 340 SOUTH KOREA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 341 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 342 SOUTH KOREA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 343 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 344 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 345 SOUTH KOREA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 346 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 347 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 348 INDIA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 349 INDIA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 350 INDIA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 351 INDIA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 352 INDIA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 353 INDIA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 354 INDIA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 355 INDIA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 356 INDIA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 357 INDIA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 358 INDIA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 359 INDIA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 360 INDIA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 361 INDIA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 362 INDIA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 363 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 364 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 365 AUSTRALIA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 366 AUSTRALIA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 367 AUSTRALIA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 368 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 369 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 370 AUSTRALIA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 371 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 372 AUSTRALIA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 373 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 374 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 375 AUSTRALIA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 376 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 377 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 378 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 379 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 380 SINGAPORE NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 381 SINGAPORE HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 382 SINGAPORE VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 383 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 384 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 385 SINGAPORE INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 386 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 387 SINGAPORE CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 388 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 389 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 390 SINGAPORE BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 391 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 392 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 393 THAILAND ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 394 THAILAND ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 395 THAILAND NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 396 THAILAND HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 397 THAILAND VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 398 THAILAND ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 399 THAILAND ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 400 THAILAND INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 401 THAILAND ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 402 THAILAND CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 403 THAILAND ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 404 THAILAND ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 405 THAILAND BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 406 THAILAND ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 407 THAILAND ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 408 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 409 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 410 MALAYSIA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 411 MALAYSIA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 412 MALAYSIA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 413 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 414 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 415 MALAYSIA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 416 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 417 MALAYSIA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 418 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 419 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 420 MALAYSIA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 421 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 422 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 423 INDONESIA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 424 INDONESIA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 425 INDONESIA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 426 INDONESIA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 427 INDONESIA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 428 INDONESIA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 429 INDONESIA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 430 INDONESIA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 431 INDONESIA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 432 INDONESIA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 433 INDONESIA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 434 INDONESIA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 435 INDONESIA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 436 INDONESIA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 437 INDONESIA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 438 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 439 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 440 PHILIPPINES NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 441 PHILIPPINES HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 442 PHILIPPINES VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 443 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 444 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 445 PHILIPPINES INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 446 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 447 PHILIPPINES CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 448 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 449 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 450 PHILIPPINES BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 451 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 452 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 453 REST OF ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 454 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET, BY COUNTRY, 2017-2026 (USD MILLION)

TABLE 455 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 456 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 457 SOUTH AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 458 SOUTH AMERICA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 459 SOUTH AMERICA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 460 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 461 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 462 SOUTH AMERICA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 463 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 464 SOUTH AMERICA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 465 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 466 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 467 SOUTH AMERICA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 468 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 469 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 470 BRAZIL ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 471 BRAZIL ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 472 BRAZIL NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 473 BRAZIL HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 474 BRAZIL VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 475 BRAZIL ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 476 BRAZIL ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 477 BRAZIL INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 478 BRAZIL ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 479 BRAZIL CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 480 BRAZIL ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 481 BRAZIL ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 482 BRAZIL BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 483 BRAZIL ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 484 BRAZIL ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 485 REST OF SOUTH AMERICA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 486 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY COUNTRY, 2017-2026 (USD MILLION)

TABLE 487 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 488 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 489 MIDDLE EAST AND AFRICA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 490 MIDDLE EAST AND AFRICA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 491 MIDDLE EAST AND AFRICA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 492 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 493 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 494 MIDDLE EAST AND AFRICA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 495 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 496 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 497 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 498 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 499 MIDDLE EAST AND AFRICA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 500 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 501 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 502 U.S. ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 503 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 504 SOUTH AFRICA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 505 SOUTH AFRICA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 506 SOUTH AFRICA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 507 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 508 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 509 SOUTH AFRICA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 510 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 511 SOUTH AFRICA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 512 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 513 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 514 SOUTH AFRICA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 515 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 516 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 517 REST OF MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19